卢司帕西普联合或不联合促红细胞生成剂治疗伴有环形铁粒幼细胞的骨髓增生异常肿瘤患者的疗效和安全性：GFM的一项多中心真实世界研究 - Suppr

Efficacy and safety of luspatercept with or without erythropoiesis-stimulating agent in patients with myelodysplastic neoplasms with ring sideroblasts: A multicentre real-life study by the GFM.

作者信息

D'Aveni Maud, Schenone Laurence, Torregrosa Jose Miguel, Pardo Jean, Stamatoullas Aspasia, Saillard Colombe, Thépot Sylvain, Dimicoli Sophie, Santana Clemence, Daguindau Etienne, Paul Francianne, Le Clech Lenaig, Park Sophie, Cluzeau Thomas, Paubelle Etienne, Taksin-Bressot Anne-Laure, Chermat Fatiha, Adès Lionel, Fenaux Pierre, Comont Thibault

机构信息

Centre Hospitalier Régional Universitaire de Nancy, Hôpitaux de Brabois, Vandèuvre-lès-Nancy, France.

Centre Hospitalier Régional Universitaire de Poitiers, Poitiers, France.

出版信息

Br J Haematol. 2025 Sep;207(3):1122-1126. doi: 10.1111/bjh.20247. Epub 2025 Jul 2.

DOI:10.1111/bjh.20247

PMID:40599042

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12436241/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a358/12436241/b827da82439e/BJH-207-1122-g001.jpg

相似文献

Efficacy and safety of luspatercept with or without erythropoiesis-stimulating agent in patients with myelodysplastic neoplasms with ring sideroblasts: A multicentre real-life study by the GFM.卢司帕西普联合或不联合促红细胞生成剂治疗伴有环形铁粒幼细胞的骨髓增生异常肿瘤患者的疗效和安全性：GFM的一项多中心真实世界研究

Br J Haematol. 2025 Sep;207(3):1122-1126. doi: 10.1111/bjh.20247. Epub 2025 Jul 2.

Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS Trial.在COMMANDS试验中，对于未使用过促红细胞生成素、低风险的骨髓增生异常综合征患者，卢司帕西普与阿法依泊汀实现长期输血独立的比较

Adv Ther. 2025 May 16. doi: 10.1007/s12325-025-03208-5.

[Luspatercept combined with roxadustat in the treatment of refractory myelodysplastic neoplasms with ring sideroblasts: a prospective, randomized, single-center study].罗特西普联合罗沙司他治疗伴有环形铁粒幼细胞的难治性骨髓增生异常肿瘤：一项前瞻性、随机、单中心研究

Zhonghua Xue Ye Xue Za Zhi. 2025 Jul 14;46(7):625-630. doi: 10.3760/cma.j.cn121090-20241126-00484.

How to use luspatercept and erythropoiesis-stimulating agents in low-risk myelodysplastic syndrome.如何在低危骨髓增生异常综合征中使用鲁索替尼和促红细胞生成剂。

Br J Haematol. 2025 Jul;207(1):15-26. doi: 10.1111/bjh.20126. Epub 2025 May 2.

Treatment patterns and outcomes in patients with lower-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents in a large US community oncology practice: a retrospective chart review.美国大型社区肿瘤医疗实践中使用促红细胞生成素治疗低危骨髓增生异常综合征患者的治疗模式及疗效：一项回顾性图表审查

J Med Econ. 2025 Dec;28(1):1357-1369. doi: 10.1080/13696998.2025.2548739. Epub 2025 Sep 2.

Oral decitabine and cedazuridine maintenance after haematopoietic stem-cell transplantation in very high-risk acute myeloid leukaemia or myelodysplastic syndrome (GFM-DACORAL-DLI): a multicentre, single-arm, phase 2 trial.口服地西他滨联合西扎苷在极高危急性髓系白血病或骨髓增生异常综合征造血干细胞移植后的维持治疗（GFM-DACORAL-DLI）：一项多中心、单臂、2期试验

Lancet Haematol. 2025 Sep;12(9):e705-e716. doi: 10.1016/S2352-3026(25)00172-3. Epub 2025 Aug 7.

Real world efficacy of luspatercept in patients with lower-risk myelodysplastic syndromes/neoplasms (MDS); a single center study in a heavily pretreated cohort.鲁索替尼在低危骨髓增生异常综合征/肿瘤（MDS）患者中的真实世界疗效：一项针对高度预处理队列的单中心研究

Leuk Lymphoma. 2025 Jul;66(7):1245-1253. doi: 10.1080/10428194.2025.2470783. Epub 2025 Mar 7.

Real-life experience of luspatercept in transfusion-dependent lower risk myelodysplastic syndrome patients.来苏特司他治疗输血依赖的低危骨髓增生异常综合征患者的真实生活经验。

Br J Haematol. 2025 Jul;207(1):101-109. doi: 10.1111/bjh.20102. Epub 2025 May 5.

Luspatercept in combination with recombinant erythropoietin in patients with myelodysplastic syndrome with ring sideroblasts: Stimulating early and late-stage erythropoiesis.来苏特生联合重组促红细胞生成素治疗伴有环形铁粒幼细胞的骨髓增生异常综合征患者：刺激早期和晚期红细胞生成

Eur J Haematol. 2023 May;110(5):571-574. doi: 10.1111/ejh.13933. Epub 2023 Feb 12.

Baseline erythropoietin level predicts Luspatercept response in Chinese patients with myelodysplastic syndrome: a propensity score-matched analysis.基线促红细胞生成素水平可预测中国骨髓增生异常综合征患者对罗特西普的反应：一项倾向评分匹配分析

Leuk Res Rep. 2025 Jul 24;24:100532. doi: 10.1016/j.lrr.2025.100532. eCollection 2025.

本文引用的文献

Experience with luspatercept therapy in patients with transfusion-dependent low-risk myelodysplastic syndromes in real-world clinical practice: exploring the positive effect of combination with erythropoietin alfa.卢司帕西普治疗输血依赖型低危骨髓增生异常综合征患者在真实世界临床实践中的经验：探索与阿法依泊汀联合使用的积极效果。

Front Oncol. 2024 Oct 2;14:1398331. doi: 10.3389/fonc.2024.1398331. eCollection 2024.

Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial.芦可替尼与红细胞生成刺激剂治疗初治、依赖输血的低危骨髓增生异常综合征（COMMANDES）：一项 3 期、开放标签、随机、对照临床试验的主要分析。

Lancet Haematol. 2024 Sep;11(9):e646-e658. doi: 10.1016/S2352-3026(24)00203-5. Epub 2024 Jul 19.

Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.骨髓增生异常综合征的分子国际预后评分系统

NEJM Evid. 2022 Jul;1(7):EVIDoa2200008. doi: 10.1056/EVIDoa2200008. Epub 2022 Jun 12.

Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts.卢司帕西普在伴有环形铁粒幼细胞的低危骨髓增生异常综合征患者中的真实世界疗效、安全性及反应预测因素

Am J Hematol. 2023 Aug;98(8):E204-E208. doi: 10.1002/ajh.26960. Epub 2023 May 24.

Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes.罗特西普与促红细胞生成素类似物联合治疗低危骨髓增生异常综合征贫血的活性

Blood Adv. 2023 Jul 25;7(14):3677-3679. doi: 10.1182/bloodadvances.2023009781.

Eur J Haematol. 2023 May;110(5):571-574. doi: 10.1111/ejh.13933. Epub 2023 Feb 12.

Real-world experience with luspatercept and predictors of response in myelodysplastic syndromes with ring sideroblasts.卢司帕西普在伴有环形铁粒幼细胞的骨髓增生异常综合征中的真实世界经验及反应预测因素

Am J Hematol. 2022 Jun 1;97(6):E210-E214. doi: 10.1002/ajh.26533. Epub 2022 Mar 29.

Clinical and Molecular Insights in Erythropoiesis Regulation of Signal Transduction Pathways in Myelodysplastic Syndromes and β-Thalassemia.骨髓增生异常综合征和 β-地中海贫血中信号转导通路的红细胞生成调控的临床和分子见解。

Int J Mol Sci. 2021 Jan 15;22(2):827. doi: 10.3390/ijms22020827.

Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management".环形铁幼粒细胞性难治性贫血（MDS-RS）和环形铁幼粒细胞性难治性血细胞增多症伴血小板增多（MDS/MPN-RS-T）伴环形铁幼粒细胞的骨髓增生异常综合征 - "2021 年关于诊断、风险分层和管理的更新"。

Am J Hematol. 2021 Mar 1;96(3):379-394. doi: 10.1002/ajh.26090. Epub 2021 Jan 28.

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.芦可替尼治疗低危骨髓增生异常综合征患者的疗效。

N Engl J Med. 2020 Jan 9;382(2):140-151. doi: 10.1056/NEJMoa1908892.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Efficacy and safety of luspatercept with or without erythropoiesis-stimulating agent in patients with myelodysplastic neoplasms with ring sideroblasts: A multicentre real-life study by the GFM.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

本文引用的文献